IP Library Granted Patent US 7,750,029
Granted Patent B2
US 7,750,029 · App. 10/534,290 · Granted Jul 6, 2010

Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Assignee: Astellas Pharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,750,029
App. No.
10/534,290
Granted
Jul 6, 2010
Kind
B2
Abstract

(R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive bladder model rat”. Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.

Claims (12)

1. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a salt thereof as an active ingredient, wherein the subject is not suffering from diabetes.

2. The method according to claim 1 , wherein the overactive bladder is a result of benign prostatic hyperplasia.

3. The method according to claim 1 , wherein the subject has urinary urgency.

4. The method according to claim 1 , wherein the subject has urinary urge incontinence.

5. The method according to claim 1 , wherein the subject has pollakiuria.

6. A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, in its free base form, as an active ingredient, wherein the subject is not suffering from diabetes.

7. The method according to claim 6 , wherein the overactive bladder is a result of benign prostatic hyperplasia.

8. The method according to claim 6 , wherein the subject has urinary urgency.

9. The method according to claim 6 , wherein the subject has urinary urge incontinence.

10. The method according to claim 6 , wherein the subject has pollakiuria.

11. The method according to claim 1 , wherein the subject is human.

12. The method according to claim 6 , wherein the subject is human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: SHIBASAKI, MASAYUKI
To: ASTELLAS PHARMA INC.
Reel/Frame 031457/0991 →
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2005
From: TAKASU, TOSHIYUKI; SATO, SHUICHI; UKAI, MASASHI; MARUYAMA, TATSUYA
To: ASTELLAS PHARMA INC.
Reel/Frame 017352/0653 →
Priority Claims (1)
JP 2002-323792 · Nov 7, 2002 · national
Continuity (1)
Related Publication 20060115540A1 · Jun 1, 2006